book earn growth
believ iqvia result demonstr mani characterist
bull wait thesi featur acceler book
momentum gener platform deploy cash drive
ep quarter iqvia deliv constant currenc growth
ahead forecast combin organ upsid higher reimburs
expens greater contribut drive beat strong technolog
analyt solut solut result drove quarterli result new
busi trend appear solid y/i ttm basi compani post net
book-to-bil ttm basi ceo bousbib note would
north quarterli basi believ repres acceler
recent trend valid compani nextgen data strategi reson
custom gross basi organ growth solut came
ahead expect acceler due recent book strength
show recent invest pay better top-lin result drove
solid ep beat vs estim driven ebitda
came expect lower share count ad
ep rel estim compani remain commit earn growth
million repurchas activ quarter
result strong quarter improv outlook iqvia rais revenu
ebitda ep guidanc revenu expect rang
billion y/i million midpoint iqvia also rais ebitda
ep guidanc reflect flow stronger oper result
commentari begun highlight valu
iqvia
differenti strategi coupl cost synergi share repurchas
believ good visibl mid-teen ep growth next sever year
reiter overweight rate rais price target
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
overweight believ iqvia creat
best class platform cro industri believ
marri quintil cro platform im clinic
insight yield market share gain time
earn growth
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid adj ebitda
risk around integr recent growth
trend integr engag solut
busi could weigh near-term growth
downsid case repres downsid
adj ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
believ iqvia result demonstr mani characterist bull
wait thesi featur acceler book momentum
gener platform deploy cash drive ep
quarter iqvia deliv constant currenc growth ahead forecast
combin organ upsid higher reimburs expens greater
contribut drive beat strong technolog analyt solut
 result drove quarterli result new busi trend appear solid
y/i ttm basi compani post net book-to-bil ttm
basi ceo bousbib note would north quarterli basi
 believ repres acceler recent trend valid
compani nextgen data strategi reson custom gross basi organ
growth came ahead expect acceler
due recent book strength technolog analyt solut post ex-fx
growth includ organ show recent invest pay
better top-lin result drove solid ep beat vs estim
driven ebitda came expect lower share
count ad ep rel estim compani remain commit
earn growth million repurchas activ quarter
result strong quarter improv outlook iqvia rais revenu
ebitda ep guidanc revenu expect rang billion
y/i million midpoint iqvia also rais ebitda ep
guidanc reflect flow stronger oper result
commentari begun highlight valu inher iqvia differenti
strategi coupl cost synergi share repurchas believ good
visibl mid-teen ep growth next sever year reiter overweight
rais price target quarter improv convict
iqvia integr strategi reson market price target
repres adj cash ebitda forecast billion prior
price target repres prior adj cash ebitda forecast
iqvia continu show progress strategi develop gener
cro ceo bousbib highlight billion award billion
attribut offer believ first increment new busi award
compani part nextgen data capabl start
contribut meaning growth importantli compani
nextgen data capabl help win busi exist client iqvia
gain traction new custom addit compani encourag win
achiev leverag nextgen platform smaller biopharma custom
client base iqvia histor under-penetrated compani note
saw growth y/i gross book emerg biopharma custom
nextgen offer play import part compani believ nextgen
offer impact roughli compani rfp volum nextgen
volum compani expand use fixed-pric contract
full thought
pleas see note
peel back curtain
new platform strategi
import data cro industri valid recent arm
race among particip believ combin compani iqvia
clear advantag rel peer last six decad im leverag supplier
relationship curat larg data set includ million longitudin de-
indentifi electron health record ehr intern access pharmaceut
script data believ global natur im data differenti combin
compani provid sell point win busi larg scale global trial
smaller trial local area specif demograph critic understand
im provid inform servic countri world-wide
combin compani leverag im core compet improv decision-
make healthcar particip focu three specif growth area build
smarter cro bolster capabl real world evid connect health
 improv commerci oper client altogeth compani believ
lever could add increment annual growth end
smarter cro iqvia plan take advantag data resourc provid
custom real-tim data-focus approach allow optim design
clinic trial leverag million ehr compani abl improv
qualiti speed clinic trial recruit process therapi thu
trial becom target complex believ im data significantli
enhanc iqvia abil locat area suffici volum patient trial
compani variou databas aggreg user-friendli platform
evid aggreg data variou sourc condens
platform capabl run queri real-tim current unmatch
industri would someth costli difficult replic final
compani aim improv execut clinic trial allow custom
increas speed market allow compani grow revenu faster
 world evid combin compani seek improv abil provid
studi evalu patient respons follow initi treatment
use im patient ehr databas compani essenti track patient health
time use team md phd compani
retrospect analyz data provid custom real world evid
addit trend allow custom make inform commerci
decis current healthcar environ heighten focu
cost valu believ solut could prove use payor
provid regul compani prior busi serv area
believ combin two creat market lead provid real
 technology-en commerci oper combin im abil provid
insight commerci decis make quintil
organ believ compani well posit support custom
iqvia rais revenu earn forecast conjunct
better result shown revenu expect rang
billion y/i vs prior guidanc billion
y/i revenu guidanc rais million midpoint
includ increment headwind million fx rais revenu guidanc
attribut better organ trend come higher anticip
pass-through revenu result greater contribut ebitda
forecast rang billion midpoint
prior rang billion compar forecast billion similarli
ep forecast rang repres growth
also prior rang repres growth y/i
compar forecast includ project adjust book tax rate
us strategyintern strategysystem investmentsia evid production platform integr legaci im data clinic develop process im coverag global pharma sale anonym patient records- infosario data factori trial engin design execut engag commerci medigaurd clinicalresearch com direct-to-pati research w/ enrol memberslabcorp covanc lh leverag labcorp patient databas patient portal clinic trial recruit biomark expertis psc use collect site patient opt leverag central lab network market share link patient site xceller custom site investig geograph select clinic trial design execution- pharmacu leverag proprietari public data provid insight guid decis includ metric benchmark trial forecast protocol optim studytrack internet-bas client access review pre-clin studi data near real-tim -integr datavers symphoni commerci health databas contain inform million live -predictivv fulli intregr program focus harmon data processess peopl across mani aspect clinic trial specif predictivv connect focus site select patient recruit investig engag -medic informat suit includ physician hospit pharmaci databas cover milllion patient live billion patient pharmaci claim syneo adheri provid multi-channel commun retail pharmaci adheri provid access pharmaci repres retail prescript total inventiv prescript data daili feed cover million patient billion rx per year parexel privat strateg allianc w/ optum give access ehr data patient claim record patientsleverag sizabl presenc employe access databas choos best site investigators- mytrial platform analyt modul analysi trial status- liquent platform manag regulatori submiss plan publish view registration- clinintel effici rtsm suit patient random clinic suppli chain solutionsicon plc iclr iconik data analysi hub- firecrest enhanc patient engag support recruitment/retention- addplan softwar leverag data design simul analyz adapt clinic trials- solut integr technolog solut conduct clinic research bring therapeut medic devic marketplaceleverag im global databas better target patient trial recruit script data ehr access combin entiti access data feed across supplier cover transact annual compani million physician record leverag site identif final leverag central lab network allow quintil link patient site patient identif trinetx live back watson comput match patient trial icon also own site network pmg research global site allianc maxim recruit compani goal recruit patient affili site low -strength data strategi highleverag inc research strong site relationship inventiv data asset facilit patient recruit site select real-world evid studi inventiv commun capabl help market clinic trial prospect patient speed enrol addit adheri platform compani ehr medic claim data leverag symphoni integr datavers platform analyt capabl provid data-driven insight optim drug develop commerci process integr datavers contain inform million live includ multi-dimension real-world evid observ invest acquir larg databas aggreg patient medic data within databas medic claim data hospit master charg data pharmaci data laboratori data payor data barclay ia
cash tax compani note complet million repurchas
quarter billion author remain
iqvia guid revenu new financi standard rang
billion impli growth y/i ebitda project
rang million y/i ep repres
growth y/i growth rate base restat financi
adjust revenu billion estim billion
upper end rang manag guidanc billion
beat driven oper momentum greater expect contribut
 higher anticip level reimburs revenu result currenc
neutral growth estim fx tailwind
revenu growth line model segment perspect result
technolog analyt solut ta solut better expect
contract sale medic solut csm line forecast repres
rev quarter iqvia renam commerci solut technolog
analyt solut ta integr engag servic contract sale
 solut revenu million grew y/i constant currenc
improv growth continu improv
appear reimburs expens came higher anticip
quarter unclear impact growth quarter total revenu
increas includ tailwind fx tailwind
result organ growth base gross revenu quarter
revenu came forecast million appear
combin organ upsid higher reimburs expens drove
upsid quarter
technolog analyt solut ta revenu million grew
report includ tailwind fx roughli contribut
acquisit organ growth came forecast
million constant currenc growth beat model
upsid quarter rel model came stronger anticip
contribut
contract sale medic solut csm revenu million declin
constant currenc weaken overal
growth declin includ tailwind fx organ growth
larg line forecast revenu also came line
estim million
iqvia post strong new book net book-to-bil base
compani old report methodolog addit compani note old
measur ttm new busi billion grew y/i repres
ttm book-to-bil iqvia provid backlog new account
standard stood billion includ reimburs expens increas
q/q fx actual sequenti headwind end backlog
recent strengthen dollar expect integr data
strategi begin reson custom time book best metric
watch earli traction
ebitda million came expect million
ebitda margin came expect may
impact fx given iqvia cost exposur margin expand quarter
constant currenc basi would expand million expect
cost synergi end track ahead compani expect
iqvia ebitda margin
cog increas y/i core sg ex-comp flat y/i remind
merger im health quintil complet octob iqvia
annual mix benefit im attract margin profil gross
estestestassumpt busi analysisr begin new y/i cancel net y/i net net y/i new net y/i recogn growth burn move average burn end growth net net ebitda margin million barclay iqvia
margin similar ebitda expect volum leverag effici initi
partial off-set invest fx headwind
iqvia cog sg revenu
ep came estim
street revenu came estim ebitda
higher expect rel guidanc ep beat expect
attribut ebitda beat tax effici lower share count partial off-set
higher interest expens
iqvia ep y/i growth
flow oper posit million adjust net
incom work capit tailwind capital-expenditure million repres
revenu y/i manag repurchas million worth share
quarter million open market million repurchas
privat equiti sponsor februari iqvia increas post-merg
author billion billion share repurchas author remain
iqvia end quarter net debt ttm adj ebitda
millionscapexfre flowiqvia except ep reportedincom currenc profit inc ebitda ebit bs pre-tax pre-tax tax net net researchprior yearprior quarter barclay iqvia
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
